Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Mã chứng khoánFEMY
Tên công tyFemasys Inc
Ngày IPOJun 18, 2021
Giám đốc điều hànhMs. Kathy Lee-Sepsick
Số lượng nhân viên69
Loại chứng khoánOrdinary Share
Kết thúc năm tài chínhJun 18
Địa chỉ3950 Johns Creek Court
Thành phốSUWANEE
Sàn giao dịch chứng khoánNASDAQ Capital Market Consolidated
Quốc giaUnited States of America
Mã bưu điện30024
Điện thoại17705003910
Trang webhttps://www.femasys.com/
Mã chứng khoánFEMY
Ngày IPOJun 18, 2021
Giám đốc điều hànhMs. Kathy Lee-Sepsick
Tổng cộng
0.00
USD đã được phân phối dưới dạng cổ tức trong 5 năm qua.

Không có dữ liệu